Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TATE vs TACE in Intermediate-Stage Hepatocellular Carcinoma
NCT06844357Phase 3Recruiting
- Sponsor
- Raygene
- Start
- Mar 2025
- Primary completion
- Apr 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of tirapazamine in hepatocellular carcinoma (HCC), sponsored by Raygene. Started Mar 2025; status: recruiting.
02
Drugs
tirapazamine
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06844357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06844357.